Positive peritoneal cytology in early stage endometrial cancer does not influence the prognosis

PM Tebeu<sup>1,5</sup>, GY Popowski<sup>2</sup>, HM Verkooijen<sup>3</sup>, F Ludicke<sup>4</sup>, M Usel<sup>3</sup>, C Bouchardy<sup>3</sup>, AL Major<sup>1,4</sup>

Departments of <sup>1</sup>Obstetrics and Gynaecology University Hospitals (UH) Geneva, UH <sup>5</sup> Yaounde, Cameroon, <sup>2</sup>Radiation Oncology UH Geneva <sup>3</sup> Geneva Cancer Registry, <sup>4</sup> Fondation pour Recherches Medicales, Geneva

#### **Epidemiology of endometrial cancer**

- 15-20 new cases per 100 000 women
- Fourth cancer in women after breast, lung and colon
- First genital tract cancer in developed countries
- Third genital tract cancer in developing countries
- Cowles et al (1985): staging change in 30.4% at surgery
- Creasman, Morrow et al (1987): out of uterus 22% (grade and myoinvasion are factors of node invasion)

#### FIGO 1971

- Stage I: Ia (less than 8 cm)
  - Ib (8 cm and more)
- Stage II: Corpus + cervix
- Stage III: Outside uterus
- Stage IV: IVa (bladder / rectal mucosa)

**IVb** : distal

#### Against FIGO 1971 clinical staging

- Musumesi et al (1980): lymph nodes 9.9% at surgery
- Aalders et al (1980): Survival 91% Vs 72% if ICG3
- Creasman al (1981): recurred 10% Vs 34% if cytology
- Kadar et al (1982): Stage II 3 cases Vs 18 at surgery
- Cowles et al (1985): staging change in 30.4% at surgery
- Creasman, Morrow et al (1987): out of uterus 22% (grade and myoinvasion are factors of node invasion)

#### **1988 FIGO**

Stage I:	Ia (epithelial invasion only) Ib (myometrial invasion <50% ) Ic (myometrial invasion >=50%)
Stage II:	corpus + cervix IIa (glands) IIb (stroma)
Stage III:	IIIa (serosa, adnexa, peritoneal cytology) IIIb (vagina) IIIc (nodes)
Stage IV:	IVa (bladder / rectal mucosa), IVb distal

## Negative Impact of positive peritoneal cytology on survival

- 1. Harouny et al (1988): (5-year disease specific survival) stage I+II: cytology negative / positive (99% Vs 83%)
- 2. Morrow et al (1991): (5-year disease specific survival) stage I+II: cytology negative / positive (93% Vs 56%)
- 3. Obermair et al (2002): (3-year disease free survival) stage I+II: cytology negative / positive (96% Vs 67%)

# No negative impact of peritoneal cytology

- 1. Grimshaw et al (1990): I cyto- Vs I cyto+
- 2. Kadar et al (1992):
- 3. Kasamatsu et al (2003):
- 4. Preyer et al (2002):

- I&II cyto- Vs I&II cyto+ (NS)
- I&II cyto- Vs I&II cyto+ (NS)
- I cyto+ Vs IIIa histologic (S)

**(NS)** 


## **Shortcomings**

	Staging	Stage	RT
Harouny et al (1988)	clinical	I & II	some
Morrow et al (1991)	clinical	I & II	some
• Obermair et al (2002)	clinical	I & II	some
Kadar et al (1992)	surgical	I & II	some
Preyer et al (2002)	surgical	I & II	some
Kasamatsu et al (2003)	surgical	I & II	some
Grimshaw et al (1990)	surgical	1	some

Tebeu et al. 2003 « Impact of peritoneal cytology on survival of endometrial cancer patients with surgery and radiotherapy »

- Surgical staging
- No cervical invasion
- All with radiotherapy
- I Vs IIIa cytologic
- Illa cytologic Vs Illa histologic

#### Disease specific survival after endometrial cancer stages I, cytological IIIa and histological IIIa



Tebeu PM et al, Br J Cancer. 2003 Dec 1 ; 89 (11) : 2023-6.

#### Survival & risk of death from cancer

#### Hazard ratios's to die from cancer (adjusted on age, grade and type of radiation)

Stage	Survival(%)	Adjusted HR	(95% CI)
1 - C	88	1	
Illa cyto.	94	0.3	(0.3 - 2.0)
Illa histo.	51	2.7	(1.0 - 7.7)

No impact of peritoneal cytology in stage I endometrial cancer: Effect of Radiotherapy?

Possible effect of adjuvant radiotherapy !!!

- So question still opened
- We need further investigations (next...)

#### **Objective**

What is the actual impact of positive peritoneal cytology on the survival of patients with endometrial cancer localised in the uterine corpus ?

## Type of study

- Population based study
- Retrospective cohort study (Geneva tumour registry) : all incident cases followed up until death.
- All cases reviewed and re-staged

## **Patients inclusion**

- Period of diagnosis 1980 1996
- Area: Swiss Canton of Geneva
- Identification: Geneva Tumour Registry
- Variables: sociodemographic factors, diagnosis, stage, ATCD, treatment within 6 months, survival

#### **Patients selection**

- Total of patients: 731
- Absence of surgical staging: 87
- Sarcomas: 24
- Other tumours: 74 (5 years before 6 months after)
- Missing information on staging / histology: 7
- Stage I & II but no cytology assessment: 139
- Final inclusion: 400

#### **Patients: final inclusion**

- **Re-staging of 400 retained patients**
- **Patients considered:** 331
- Stage I: (no radiation: 149, radiation: 129) 278
- (no radiation: 6, radiation: 27) **Stage IIIa cytologic:** 33
- **Stage IIIa histologic:**

(no radiation: 5, radiation: 15) 20


### **Statistical analysis**

- 5-year specific survival
- SPSS software
- Kaplan-Meier method
- Log-rank test
- Cytology impact and mortality: Cox modelling


#### **Results - 1**

- 5-year survival for all patients
- Stage I / Illa cytologic (92.3% Vs 90.9%)
- Stage IIIa cytologic / IIIa histologic (90.9% Vs 49.5%)
- Prognosis unchanged whether or not radiation
- Radiation improve prognosis of IIIa histo. (60.0% Vs 20.0%)


#### **Results 2: Survival for all cases**



#### **Results 3: cases with radiotherapy**



#### **Results 4 : cases without radiotherapy**



#### **Results - 5**

#### Hazard ratios's to die from cancer (adjusted on age, grade, myometrial invasion, radiation)

Stage	survival(%)	adjusted HR	(95% CI)
I.	92.3	1	
IIIa cytologic	90.9	0.74	(0.18-2.3)
IIIa histologic	49.5	4.18	(1.7-10.3)

#### Conclusions

- Study with few shortcomings
- Same survival for stage I and IIIa cytologic
- Different survival for stage IIIa cytologic and stage IIIa histologic
- For better validity and reliability, FIGO should consider reviewing the 1988 staging of endometrial cancer

#### **Aknowledgements**

- Departementst of Obstetric-Gynecology +HUG
- Departementst of Radiation Oncology HUG
- Geneva Tumour Registry IMSP University of Geneva
- Fondations pour Recherches Médicales, University of Geneva
- Geneva League Against Cancer
- Cameroon Swiss Cooperation



#### NICE WEEK-END